CHURCHILL MANAGEMENT Corp boosted its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 223.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,801,330 shares of the financial services provider’s stock after purchasing an additional 1,244,066 shares during the period. iShares NASDAQ Biotechnology Index accounts for approximately 4.2% of CHURCHILL MANAGEMENT Corp’s portfolio, making the stock its 9th biggest position. CHURCHILL MANAGEMENT Corp’s holdings in iShares NASDAQ Biotechnology Index were worth $192,328,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FNY Partners Fund LP purchased a new stake in iShares NASDAQ Biotechnology Index in the third quarter valued at approximately $133,000. North Star Investment Management Corp. boosted its position in iShares NASDAQ Biotechnology Index by 575.0% in the fourth quarter. North Star Investment Management Corp. now owns 1,350 shares of the financial services provider’s stock valued at $144,000 after buying an additional 1,150 shares during the last quarter. Leavell Investment Management Inc. boosted its position in iShares NASDAQ Biotechnology Index by 200.0% in the fourth quarter. Leavell Investment Management Inc. now owns 1,920 shares of the financial services provider’s stock valued at $205,000 after buying an additional 1,280 shares during the last quarter. Wharton Business Group LLC purchased a new stake in iShares NASDAQ Biotechnology Index in the third quarter valued at approximately $208,000. Finally, New England Investment & Retirement Group Inc. purchased a new stake in iShares NASDAQ Biotechnology Index in the third quarter valued at approximately $213,000. Hedge funds and other institutional investors own 21.10% of the company’s stock.

Shares of iShares NASDAQ Biotechnology Index (IBB) traded up $0.32 during midday trading on Thursday, reaching $111.23. The company had a trading volume of 1,770,779 shares, compared to its average volume of 2,832,221. The stock has a market capitalization of $10,290.00, a price-to-earnings ratio of 3.67 and a beta of 1.38. iShares NASDAQ Biotechnology Index has a 52-week low of $88.96 and a 52-week high of $114.17.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 22nd were given a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 0.45%. The ex-dividend date was Thursday, December 21st. This is a positive change from iShares NASDAQ Biotechnology Index’s previous quarterly dividend of $0.04. iShares NASDAQ Biotechnology Index’s dividend payout ratio is currently 2.38%.

TRADEMARK VIOLATION WARNING: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/11/ishares-nasdaq-biotechnology-index-ibb-is-churchill-management-corps-9th-largest-position.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Stock Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related stocks with our FREE daily email newsletter.